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Xanthone dimers are a widespread, structurally-diverse family of natural products frequently found in plants,
fungi and lichens. They feature an intriguing variety of linkages between the component xanthones
(benzannulated chromanones). These synthetically elusive secondary metabolites are of great interest
due to their broad array of bioactivities, which has led to the xanthones being designated as ‘privileged
structures’. We seek herein to give an overview of all reliably-described xanthone dimers, their
structures, occurrence, and the bioactivities established to date. The possible biosynthetic pathways
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Xanthones comprise a group of structurally diverse, biosyn-
thetically intriguing, biologically active and synthetically chal-
lenging natural products. Many xanthones have been found to
exhibit pronounced biological activities, for example anti-
tumour effects.1–5 Xanthone chemistry is satisfyingly rich, with
the conjugated donor–acceptor motif of the central B-ringThis journal is © The Royal Society of Chemistry 2015

























































































View Article Onlineensuring that these compounds display a degree of personality
greater than their apparently simple core structure might
suggest.
The xanthone family has been studied for over a century
since the early 1900s6,7 and has since been investigated and
reviewed, particularly for the monomeric species and plant-
derived species.8–14 Several reviews on xanthones have been
published in recent years, covering xanthones from fungi,15
lichens and bacteria,16 structure–activity relationships,2 anti-
malarial properties of xanthones,17 biological activity,18 chem-
ical synthesis of xanthone cores,19–21 and their biosynthesis.22–27
Nonetheless, the eld of xanthone chemistry is growing rapidly;
every few years see the publication of an update on novel
naturally-occurring xanthones.8,21,28–30 Analytical techniques
have been optimised specically for xanthones, including
crystallography31 and chromatographic methods.32 TheTim Wezeman is a PhD candi-
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This journal is © The Royal Society of Chemistry 2015structure, activity and synthesis of polycyclic, yet monomeric
xanthones has recently been reviewed,33 as well as the specic
class of the caged xanthones.34,35 Most of these articles focus
mainly on monomeric xanthones, and to date none have
focused on dimeric and trimeric xanthones.
For the sake of simplicity and easy comparison between
structural features, structural numbering will follow the
monomeric parent xanthone core (1, Fig. 1) throughout this
review.2 Biosynthesis
The biosynthesis of dimeric xanthones is a topic which stands
in need of further research progress, especially the identica-
tion and description of the key dimerisation processes (see also
ref. 15 and 16). As the biosynthesis of the dimeric structures is a
point of considerable interest and remains largely unknown, we
will give a necessarily brief outline of the achievements so far –
the full elucidation of the biosynthesis is no doubt just over the
horizon.2.1 Monomer xanthones
It has been known for some time that the biosynthesis of the
monomeric xanthone core proceeds differently in fungi25,36 and
higher plants (Scheme 1).37,38 The synthesis of the xanthones in
fungi has been studied in detail since the radiolabelled acetateStefan Bräse studied in
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View Article Onlinefeeding experiments of Birch in the 1950s, showing that poly-
ketides are the biosynthetic precursors of the xanthone core for
fungi. More recently, Simpson has reported ndings resulting
from the sequencing of the Aspergillus nidulans genome.39 The
sequencing revealed the presence of 32 clusters containing
polyketide synthase (PKS) genes, which were studied by gene
deletion to reveal information about the biosynthetic pathway
which converts emodin via key steps of oxidative ring-scission
and decarboxylative cyclisation to xanthones and eventually
prenylated and cyclised products such as shamixanthone,
tajixanthone and sterigmatocystin. As part of a comprehensive
study on the formation of aatoxin in Aspergillus species,
Townsend and co-workers described the generation of xanthone
monomers through a complex sequence of epoxidation, rear-
rangement, deoxygenation, Baeyer–Villiger oxidation, and
further deoxygenation leading to the tricyclic xanthone core of
sterigmatocystin.40 Interpretation of the sequences may differ
markedly41 in terms of the sequence of events, and the struc-
tural homology of biomolecules involved in the pathway in
differing species may not, in fact, be a reliable method for
determining correlations between pathways.
Müller and co-workers have recently discussed the impor-
tance of reductive steps in the synthesis of xanthones
commencing from (polyketide-derived) anthraquinone,
emodin, and passing through chrysophanol.42 Contrastingly,
the biosynthesis of xanthones in plants results from a conver-
gent synthesis of polyketide and shikimic acid pathways,
whereby 3-hydroxybenzoyl-CoA (obtained from an early shiki-
mate pathway intermediate) is condensed with a polyketide,
which may be then cyclised to form the C-ring and then the
B-ring.26 A consequence of these two distinct pathways, both of
which pass through a freely-rotatable benzophenone interme-
diate, is that the pattern of oxidation between xanthones from
plants and fungi frequently differs. Fungal xanthones (or their
biosynthetic precursors) almost ubiquitously display C-1 and -8-
hydroxylation, whilst plants frequently display C-1, -3 and -5 or
-7-hydroxylation.
In terms of further diversication of the xanthone core, some
processes are now understood better than others. The investi-
gations of Elix and co-workers have led to a fuller understanding
of some of the pathways of further structural elaboration of the
xanthone nucleus in lichens. Particularly, cladistical/phyloge-
netic analysis of related species was studied to develop a fuller
understanding of the relationship between enzymes respon-
sible for methylation and chlorination.43,44 Prenylation of the
dimers is frequently found in plant-derived xanthones.45
Pendant sugars are also found as a structural feature of dimers,
see for example puniceaside C (72, plant derived) and Hirtus-
neanoside (120, lichenoid). It is also known that some substit-
uents are removed from the xanthone core, such as the
reduction of hydroxyl functions and reductive dearomatisation.Scheme 1 Xanthone biosynthesis differs in plants and fungi.2.2 Xanthone dimerisation
There are a variety of ways in which dimeric and trimeric
xanthones can be linked: (i) a rotatable or atropisomeric biaryl
C–C bond or (ii) a biaryl ether C–O–C linkage. Also, because8 | Nat. Prod. Rep., 2015, 32, 6–28xanthones, particularly from plants, can be decorated with
prenyl groups, the linkages are also oen in the form of (iii)
aryl–O–alkyl linkages, or (iv) prenyl derivative–prenyl derivative
linkages. The incorporation of nitrogeneous bases to form

























































































View Article Onlineand readers are directed to the recent review by Porco and co-
workers on this subject.33
One of the more common ways in which dimerisation is
found in the xanthones is through the biaryl linkage. Regio- and
stereo-selective biaryl linkage of phenolic compounds is
common in plants, bacteria, lichen, and fungi – as Bringmann
and co-workers noted in their seminal work on natural biaryl
linkages, “wherever in Nature phenolic aromatics can be
found. the corresponding homo- or hetero-dimeric biaryls
have to be expected”.46 Certainly, the discovery of the blenno-
lides (hemisecalonic acids)47 in 2008 supported the putative
dimerisation of discrete monomers as the likely method of
dimer formation, rather than a more complex and difficult to
imagine tandem biosynthesis pathway – the side-by-side cycli-
sation of a double-length polyketide to form e.g. a secalonic acid
seems unlikely. Despite efforts in the detailed study of the
biosynthesis of dimeric xanthones, particularly of the secalonic
acids by Frank and co-workers,23,40,48–50 the dimerisation of
xanthones remains a tricky subject for both the synthetic and
biosynthetic chemist – the extent of the involvement of
enzymes, and their nature, is at present unclear. There has
been, at the time of writing, no direct observation of enzymatic
dimerisation of the monomer units.Scheme 2 Phenolic dimerisation reactions adapted for xanthones. For
clarity, coupling of 16a–c at the ortho-position of 14 is shown.
This journal is © The Royal Society of Chemistry 2015Enzymatically-mediated or not, the oxidative pathway which
is most commonly invoked is shown here (Scheme 2), whereby
single electron transfer deprotonation of a hydroxyxanthone,
14, leads to an intermediate which can be readily oxidised by
single-electron-transfer to xanthonyl radical 16. Resonance
contributors of the delocalised aryl radical, 16a–c, can then
couple to electron-donors, notably the ortho and para-C
positions.2.3 Regiochemical evidence for enzyme dimerisation
The resulting biaryl bond linkages are formed which, in the
absence of an enzyme or other structurally-inuencing
substrate, is determined largely by the spin-density distribution
of the radical generated, and presumably in some cases other
inherent stereoelectronic characteristics of the substrate mole-
cule. As Kozlowski has put it, in the absence of external factors,
“the substrate typically dictates the available coupling prod-
ucts”.51 This leads us, as chemists, to an interesting corollary – if
there are differing regio- and atropo-isomeric biaryl-linked
dimers of the same substrate to be found in Nature, then it must
be the case that there are external forces at play in their
biosynthesis to lead to this divergence, rather than ‘sponta-
neous’ oxidative dimerisation with oxidants such as intracel-
lular O2. Prominent examples supporting this line of thinking
can be seen in Scheme 3, where both secalonic acid B/chrys-
oxanthone and secalonic acid E/talaroxanthone are presumably
generated with alternative (chemo- and regio-) selectivity from
the monomer units, hemisecalonic acids B and F, respectively.
The oxidative dimerisation of the xanthones is thus most likely
mediated by enzymes, as shown for a number of model
compounds.52–54 It can be mimicked by chemical oxidases.55 In
some cases, the dimerisation led to the formation of diaryl
ethers (e.g. chrysoxanthone 22, Scheme 3) instead of to a C–C
bond formation.
Hemisecalonic acid B47 is dimerised at the ortho-positions to
form secalonic acid B 21 (Scheme 3; see below for more infor-
mation) in a variety of fungal species.49,148–150,153 From the same
substrate in the case of the xanthone anthraquinone chrysox-
anthone, the coupling of the hemisecalonic acid B with a
2-hydroxy variant of chrysophanol, a widespread polyketide
natural product, dimerisation leads to the C–O bond formation
of diaryl ethers i.e. chrysoxanthone.56 Another example of
biosynthetic divergence is likely involved in the regioisomeric
selectivity which leads to the formation of talaroxanthone 25, a
4,40-linked xanthone dimer (from the endophytic fungi
Talaromyces sp.)57 and secalonic acid E 24, a 2,20-linked
xanthone dimer (from e.g. Phoma terrestris).58,59 That a statistical
mixture of the three regioisomers is produced by each of the
organisms in question and the two differing regioisomers have
been selectively isolated by the research groups in each case is
highly unlikely (see Scheme 3). The selective discovery of these
regioisomers can therefore be considered indirect evidence for
the active role of yet-to-be discovered enzymes.
In the laboratory, regioisomeric control over the biaryl bond
formation60–62 is oen difficult to impose, and frequently
requires innovative solutions.63–66 In natural biosynthesis, it hasNat. Prod. Rep., 2015, 32, 6–28 | 9
Scheme 3 Multiple pathways from the same monomer units strongly
suggest the involvement of enzymatic processes in xanthone
dimerisation.
Scheme 4 The synthetic usage of laccase enzymes in biphenolic

























































































View Article Onlinebeen demonstrated that selectivity between 2,20- 2,40- and 4,40-
coupling can presumably be imposed by enzymes, although
little direct evidence exists for this – no enzyme has yet been
identied which fulls the role of regioselective differentiation
in the dimerisation of xanthones in Nature. Nonetheless, high
selectivity for such processes has been demonstrated with
enzymes in the laboratory; oxidative dimerisation at a specic
ortho-position to form ferulic acid derivatives has been reported
by Beifuss and co-workers, and has been achieved by applica-
tion of the (single electron) oxidase enzyme67,68 laccase,69 from
Trametes versicolor, in the presence of O2.70 Additionally, selec-
tive coupling at the C-6 position of sesamol led to dimer inter-
mediates and then trimers in good yield.71 The outcome was10 | Nat. Prod. Rep., 2015, 32, 6–28markedly different than in the application of laccase from
Agaricus bisporus, and also from electrochemical non-enzymatic
oxidative coupling of this substrate by the method of Waldvogel
and co-workers.72,73 Aside from their potential relevance to
xanthone dimerisation, the synthetic application of enzyme-
catalyzed transformations has signicant additional benets:
they can be performed in aqueous solvent systems and under
mild reaction conditions, a remarkably broad substrate spec-
trum that can be expanded even more by using mediators
(Scheme 4).74
It is therefore logical to support the assertion of Bringmann and
co-workers that the dimerisation of phenolic aromatics (both C–C
and C–O coupling) is through “ – mostly – enzymatically-assisted
biogenetic pathways”.41 Based on related processes in the chemical
literature on both natural products75–79 and synthesis,80–82 one
possibility is that a laccase is responsible. Another possibility is a
monooxygenase, such as cytochrome P450; evidence for a likely
mechanism for stereoselectivity is also found in this case.2.4 Stereochemical features of the biaryl xanthone dimer
Substituted biaryls exhibit varying degrees of barrier to rotation,
ranging from freely rotating (microsecond time-frame) through
slow room-temperature interconversion to atropisomers which
may be isolable and thereaer stable; dimeric xanthones show
this feature also. Stereochemical biaryl bond formation is dis-
played in the secondary metabolism of bacteria, fungi, lichens
and plants, and has herein been denoted alongside the struc-
tures of biaryl-linked dimers utilising the notation of Bring-
mann and co-workers (see Scheme 5).44 As both chiral andmeso-
dimers have been found in the secalonic acid series, various
mechanisms for the origin of the dimers can be invoked. The
reasons for this could certainly be due to the different biosyn-
thesis routes employed between the classes of species. In fungi,
all xanthone dimers display a biaryl xanthan–xanthone bond
between one or more di- or tetra-hydro xanthones. It couldThis journal is © The Royal Society of Chemistry 2015


























































































View Article Onlinepossibly be argued that the dimerisation process could be
inuenced by the asymmetrically-substituted C-ring, a possible
explanation for non-enzymatic axial chirality generation.
However, the fully aromatic xanthone dimer ploiarixanthone
68, which is optically active ([a]25D ¼ +23),83 must involve axial-This journal is © The Royal Society of Chemistry 2015chirality inuencing biomolecules in the stereospecic dimer-
isation step.
The involvement of stereoselectivity-mediating proteins may
prove to be the origin of stereospecic pathways in the formation
of dimeric xanthones. One case where the explanation for the
regio- and stereo-chemical control observed in a biphenolic
coupling has been uncovered is the mechanism of selective
phenol coupling in Aspergillus niger by Müller and co-workers.54
They showed that an oxidative phenol coupling is also the key
stereo-divergent step in the formation of P-(+)-kotanin (33,
Scheme 5) from two equivalents of coumarin 31 catalyzed by
cytochrome P450 monooxygenase KtnC, which was identied by
targeted gene deletion in the A. niger strain. The facially-selective
interaction of the two monomer subunits with the heme-con-
taining active site of the CyP450 was modelled in silico by
homology studies and docking of both the substrates and
product. Stipanovic and co-workers showed enzymatic coupling
of hemigossypol (35, Scheme 5); this compound by in vitro
application of a pure peroxidase only led to a racemic product
()-gossypol, whereas the addition of a cotton-plant dirigent
protein gave predominantly (+)-(S)-gossypol.84a Naturally-occur-
ring gossypol is found as a mixture of (+) and () isomers, which
have been found to exist in a continuum of ratios between 68 and
2% ()-(R)-gossypol, depending on the strain of the cotton plant
G. barbadense,84b possibly indicating a variation in the type or
extent of dirigent protein control in the coupling. Stereoselective
phenol coupling of 37 resulting in C and O–alkylation products
(+)-38 or racemic 39 and 40, reminiscent of the kind of trans-
formations of some linked and/or cyclized dimeric xanthones,
has also been achieved with a combination of laccase and diri-
gent protein FiDIR1.85 It may be the case that for xanthones there
are also mediator proteins associated with oxidase enzymes
involved in the stereoselective generation of the biaryl bonds.
The absolute stereochemical assignation of regioisomeri-
cally identical xanthone dimers isolated from different biolog-
ical sources is, unfortunately, in many cases incomplete. X-ray
structures have been used to determine the relative and abso-
lute stereochemistry of the stereochemical centres and axes (e.g.
for phomoxanthone A 106 and phomalevone A 103).86 In some
cases, however, modern DFT calculations have allowed CD
spectra to be computed which were used for comparison with
experimental data (blennolides).47 In particular, the quantita-
tive consideration of vibronic effects, conformer equilibria and
solvent effects were included in most of the models.87 As bio-
logical activity and their biological targets are different for
different diastereomers (e.g. compare secalonic acid A and E), it
is very important to address stereochemical issues of dimeric
xanthones. Unfortunately, many data are not available (due to
the lack of instrumentation and/or authentic material).2.5 The true biological sources of xanthone dimers?
In some cases researchers have reported dimeric xanthones as
being isolated from endophytes.57,86,88–90 Certainly culture broth
production of dimeric xanthones has demonstrated that this
class of molecules can be produced by fungi alone. This raises

























































































View Article Onlinethe true producers, or fungi? Is there amixed origin, or is it really
only the (undetected) fungi which produce the xanthone dimers?
For monomeric xanthones, the plant–fungus contributions
have been at least partially unveiled on at least two occasions. In
its biosynthesis, the monomeric xanthone 2,7-dichlorolichex-
anthone (not shown) was isolated from samples of the lichen
Lecanora dispersa. In cultures of the fungal species in the
absence of the alga, the xanthone biosynthesis was halted.91 In
an example for xanthone dimers, the eumitrins (see below) are
produced by the lichen (algae-fungal symbiotic organism), and
not by only the fungus in isolation.92 It is conceivable that in
some situations that involve plant-microbe combinations, the
biosynthesis may even involve a to-and-fro sequence of enzy-
matic transformations carried out by each organism. Such a
scenario, if it does exist, is likely to be complex and case-specic.3 Xanthone dimers from plants
Xanthone dimers from plants, like the monomers themselves,
commonly feature prenylated and multi-prenylated cores. The
presence of these many prenylated monomeric xanthones
shows that prenylation occurs readily prior to dimerisation,
although there is no evidence to suggest that it does not also
occur post-dimerisation.3.1 Bijaponicaxanthones
Several interesting xanthones were isolated from the ethanol
extracts of the dried aerial parts of Hypericum japonicum, a
Chinese medicinal plant, including one dimeric xanthone
named bijaponicaxanthone (41). By comparing the NMR spectra
with known compounds such as the monomeric xanthone iso-
jacareubin (not shown), and by analysing additional 2D NMR
spectra, its structure could be assigned. The relative congura-
tion between the two chiral centres was determined to be cis for
the two protons, based on their coupling constant.93–95In 2005, a similar dimeric xanthone was isolated from
Hypericum japonicum. Aer detailed structural analysis the12 | Nat. Prod. Rep., 2015, 32, 6–28xanthone was found to be prenylated instead of having a fourth
ring and the natural product was named bijaponicaxanthone C
(42).96 Bijaponicaxanthone C was also reported to have been
isolated from the roots of the Hypericum riparium plant.97
3.2 Bixanthones
The structurally very similar bixanthones C and D (43, 44), as
reported in a Chinese patent, were also isolated from Hypericum
japonicum. The patent claims these compounds are active
ingredients in a traditional Chinese medicine which is used to
treat a variety of liver diseases, and describes the use of the
avone component of that plant species as a medicament for
treating hepatic brosis.98 These compounds are missing OH
groups on the furannulated xanthone component, presumably
due to enzymatic reduction.
3.3 Bigarcinenones
Since the plant Garcinia xanthochymus is widely used as tradi-
tional Chinese medicine, Yang et al. investigated the extracts
from the bark of the plant. They observed a strong antioxidant
activity (IC50: 4.6 mg mL
1, as determined by a 1,1-diphenyl-2-
picrylhydrazyl (DPPH) radical scavenging bioassay) in the ethyl
acetate soluble fraction from the ethanol extracts, and pro-
ceeded with a more detailed study on the contents of these
extracts. Along with seven known xanthones, they found a novel
bisxanthone called bigarcinenone A (45).
Using mainly 2D-NMR techniques, the authors identied the
dimeric xanthone to be coupled through a side-chain of one of
the two subunits. Bigarcinenone A performed relatively well in a
DPPH radical scavenging activity assay (IC50: 9.2 mg mL
1),
outperforming all other isolated xanthones from this extract
(IC50: 16.3–250 mg mL
1) as well as BHT (IC50: 20.0 mg mL
1), a
well-known synthetic antioxidant.99 In 2011, bigarcinenone B
was isolated from the bark of the same plant and its structure
and relative stereochemistry was also elucidated using mainly
2D NMR techniques such as HMBC, HSQC and ROESY. A
possible biosynthetic pathway was proposed by the authors that
would lead to the unique connection through the two six
membered rings. A Diels–Alder reaction between the two prenyl
groups of the monomers would lead to the cyclohexene deriv-
ative, which would undergo a second cyclisation to form the
nal ring. The antioxidant activity of bigarcinenone B (7) was
tested with a DPPH assay (IC50: 20.14 mM versus 13.16 mM for
ascorbic acid) and a H2O2 assay (IC50: 2.85 mM versus 0.76 mM for
ascorbic acid).100This journal is © The Royal Society of Chemistry 2015
Scheme 6 Proposed biosynthetic coupling of twomangostin-derived

























































































View Article Online3.4 Chiratanin
An interesting biaryl-ether linked dimeric xanthone named
chiratanin (47) was isolated together with several monomeric
xanthones and other secondary metabolites from the benzene
extracts of the plant Swertia chirata.101 At the time, this was the
rst report of the occurrence of a dimeric xanthone in a higher
plant. Aer detailed analysis of the NMR spectra, the authors
identied the positions of the oxygen atoms in the molecule,
and with D2O exchange experiments all the phenolic hydroxyl
groups were identied. However, the actual connection of the
two xanthones remained difficult to determine, and three
possible structures were identied. The molecular asymmetry
was instructive in determining the nal structure, which they
named chiratanin.
3.5 Cratoxyxanthone
Several natural products were isolated from the bark of Cra-
toxylum cochinchinense in 1995 by Sim et al.102 Aer extensive
HPLC purication of the isolated compounds, detailed highThis journal is © The Royal Society of Chemistry 2015eld NMR spectroscopy was used to identify a novel dimeric
xanthone, named cratoxyxanthone (48).
The authors speculated on a biosynthetic pathway involving
the coupling of two mangostin-derived radicals, as depicted in
Scheme 6. Cratoxyxanthone was also isolated from the chloro-
form soluble extracts of the stem bark of Garcinia mangostana in
2009.103 In this study, it was found that cratoxyxanthone had a
very poor in vitro activity in cytotoxicity (HT-29 cell line) and
ELISA NF-kB (p65 and p50) assays.3.6 Garcilivins A–C
Bark from the roots of the South African plant Garcinia
livingstonei was phytochemically investigated in a larger study
aiming to nd reversible monoamine-oxidase inhibitors for
antidepressant drugs. This study resulted in the discovery of
several prenylated xanthones, including three dimeric
xanthones named the garcilivins (51–53).104 The structures were
elucidated using extensive mass and NMR spectroscopy and by
comparing with monomeric xanthone spectra.105 In 1992 it was
reported that these xanthones were currently being assayed for
their biological activities, but as far as the authors know, no
follow-up paper was published until Pieters et al. in 2006.106
They report the isolation of several xanthones and avonoids
from a Tanzanian G. livingstonei and tested the isolated
compounds for their antiparasitic activity and cytotoxicity.
Garcilivin A and C showed a very interesting difference in their
toxicity tests, considering they are diastereoisomers. Both
compounds were tested against four parasites and garcilivin ANat. Prod. Rep., 2015, 32, 6–28 | 13

























































































View Article Onlineshowed a very strong non-selective activity in all the assays,
whereas garcilivin C only showed signicant activity against
Trypanosoma brucei. Especially noteworthy is the score for
cytotoxicity against MRC-5 cells of 2.0 mM for garcilivin A and
52.3 mM for garcilivin C.
3.7 Garciobioxanthone
Recently, the novel garciobioxanthone (54) was isolated from
the ethanol extracts from the bark of Garcina oblongifolia, along
with several known compounds. Using 2D NMR techniques the
relative conguration and structure was determined.107
3.8 Globulixanthone E
Three prenylated xanthones were isolated from the root bark of
the large forest tree Symphonia globulifera and named glob-
ulixanthone C–E. The tree is widely used in Cameroon as a
medicinal plant and laxative for pregnant women. Globulix-
anthone C and D were found to be monomeric xanthones, but
globulixanthone E was found to be a bisxanthone and its
structure (55) was elucidated using ESI-TOF MS, IR and NMR
spectroscopic methods. Using NOESY spectra and by
comparing the obtained spectra with the other isolated
xanthones, the structure was determined. The three xanthones14 | Nat. Prod. Rep., 2015, 32, 6–28were tested for their in vitro antimicrobial activities against
Staphylococcus aureus, Bacillus subtilis, Vibrio anguillarium and
Escherichia coli in an agar well diffusion assay. The monomeric
xanthones showed a moderate activity to S. aureus (MIC: 8.05–
14.05 mg mL1) and B. subtilis (MIC: 8.24–12.5 mg mL1), but
globulixanthone E showed a remarkably high activity against all
tested organisms (MIC: 5.56–3.12 mg mL1) except E. coli, and
outperformed the positive control in the case of S. aureus (MIC:
4.51 mg mL1 versus 6.25 mg mL1 for streptomycin sulfate).108
3.9 Griffipavixanthone
An investigation into the secondary metabolites of the Malay-
sian plants Garcinia pavifolia and G. griffithi lead to the
discovery of a new bisxanthone named griffipavixanthone.109
Using advanced spectroscopic methods, including NOESY,
HMBC and INEPT NMR studies, the relative structure was
elucidated. In a later study, the bisxanthone was also found in
G. maingayii.110 Griffipavixanthone was the rst example of a
dimeric xanthone that is connected via a 5 and a 6 membered
ring.109 The authors suggest a possible biosynthetic pathway

























































































View Article Onlinethe two xanthones (Scheme 7). The resulting cyclohexene is
then followed by another cyclisation, either ionic or radical, to
yield the 5-membered ring. The bisxanthone was also isolated
from Garcina oblongifolia107 (along with several other xanthones,
such as garciobioxanthone) and G. virgate111 (along with two
new monomeric xanthones named virgataxanthone A and B,
not shown). The isolated compounds in the latter study were
tested for antioxidant capacity, and it was noted that griffipa-
vixanthone showed a notably high radical scavenging ability,
with an EC50 lower than the references used in the study (EC50:
griffipavixanthone: 11.5 mg 100 mL1, 2,6-di-tert-butyl-4-
hydroxy-anisol: 13.6 mg 100 mL1, a-tocopherol: 13.8 mg 100
mL1). In in vitro cell line cytotoxicity tests griffipavixanthone
showed high activity against P388, LL/2 and Wehil64 cell lines
with very promising ED50 between 3.40 and 6.80 mg mL
1.109 A
Chinese patent reports promising anti-cancer properties for
griffipavixanthone. They claim a strong inhibition effect of the
bisxanthone or its salts on human lung, breast, prostatic and
intestinal cancer cells, while showing no cytotoxicity to normal
kidney epidermal cells. For lung cancer cells H520 in particular,
they found that the cell cycle was blocked in the S stage, thereby
preventing propagation of the cancers.1123.10 Hyperidixanthone
Hyperidixanthone (60) is a symmetrical dimer isolated from the
plant Hypericum chinense.113 The compound was identied by a
barrage of NMR techniques, including HMBC, and mass spec-
tral data. Although hyperidixanthone is almost certainly axially
chiral, the authors reported no details of optical activity.
3.11 Jacarelhyperols A, B and D
Jacarelhyperols A and B (61, 62) were isolated from Hypericum
japonicum only a few years later than the bijaponicaxanthones,
and the measured NMR spectra were found to be very similar to
the spectra obtained from the bijaponicaxanthones. The relative
structure of jacarelhyperol A was elucidated to be an epimer of
bijapoincaxanthone with a trans-conguration of the two protons
at the chiral centres. Jacarelhyperol B was subsequently identied
as a 60-dehydroxy variant of jacarelhyperol A. Both jacarelhyperols
A and B were found to signicantly inhibit platelet-activating
factor (PAF)-induced hypertension in mice at 10 mg kg1 without
causing their blood pressure to rise. Therefore PAF inhibitors are
considered to be potential drugs against allergic diseases.114 The
isolation and structure elucidation of jacarelhyperol D from theThis journal is © The Royal Society of Chemistry 2015same plant species was reported in 2007 in a short communi-
cation paper by Chen et al.1153.12 Mesuabixanthones A and B
The bark of the south-east Asian tree Mesua ferrea has been
widely used in traditional local medicine and is reported to
exhibit antimicrobial and antiasthmatic activity. Therefore, the
stem bark was investigated in an attempt to isolate the active
compounds. Interestingly, the two novel bisxanthones mesua-
bixanthone A and B (64, 65) were isolated from an extracted
fraction that showed little biological activity in their initial
bioassays. Using conventional mass spectrometric and NMR
spectroscopic methods they identied the two novel bisxan-
thones. Mesuabixanthone B differed from mesuabixanthone A
only by the methylation of the hydroxyl group at C-8, as deter-
mined by a NOESY experiment. No biological testing on the

























































































View Article Online3.13 Mesuferrols A and B
The very similar mesuferrols A and B (66, 67) have been isolated
from an acetone extract of the bark of the same tree and were
puried using chromatography.117 Mesuferrol A and B were
identied by means of NMR spectroscopy and HR FAB-MS.3.14 Ploiarixanthone
In 1990 a novel dimeric xanthone metabolite was isolated from
branches of the shrub Ploiarium alternifolium. By synthesising a
tetracetylated derivative and detailed comparison of the
obtained NMR spectra with the data from the natural product,
they identied ploiarixanthone (68) to be 8,80-linked.83 Ploiar-
ixanthone is optically active ([a]25D ¼ +23), providing strong
evidence for an enzymatic dimerisation process in its
formation.
3.15 Puniceasides
In 1991 the rst isolation and structure elucidation of a bis-
xanthone C-glucoside named swertipunicoside (77a, Fig. 2) was
reported. It was isolated from extracts from the whole plant
Swertia punicea and the structure was conrmed by NMR
experiments, particularly the selective INEPT technique
(Insensitive Nuclei Enhanced by Polarisation Transfer).118 Only
one year later the same group was also able to isolate and
characterise 3-O-demethylswertipunicoside (77b) using several
NMR techniques including APT, HETCOR and selective
INEPT.119 Puniceasides B and C and isopuniceaside B have all
been partially reduced to feature one tetrahydroxanthone core.
Recently, investigations showed that 3-O-demethylswertipu-
nicoside has potent neuroprotective capabilities. Several
oxidative toxicity tests were performed on xanthone treated and
untreated PC12 cells. Increased cell viability was found in a
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) cell death assay where the cells were exposed to 1-methyl-
4-phenylpyridiniumion (MPP+), rotenone or hydrogen peroxide.
These neuroprotective effects were found to be caused by the
elevation of TH and DJ-1 protein levels.120
Hostettmann et al. isolated several xanthones from Gentia-
nella amarella ssp. acuta, including one new dimeric xanthone.
Aer structure elucidation with the use of 2D-NMR experiments
and mass spectrometry they named the compound swertia-
bisxanthone I 80-O-b-D-glucopyranoside (73b).121
Remarkably, its aglycone, swertiabisxanthone I (73a), was
rst isolated and identiedmore than twenty years earlier from
Swertia macrosperm plants.122 Recently both the glycone and the
aglycone of swertiabisxanthone I have also been isolated from16 | Nat. Prod. Rep., 2015, 32, 6–28Swertia punicea.123 In 2010, Guo et al. isolated two new dimeric
O-glycoside xanthones, one new trimeric O-glycoside xanthone,
two new trimeric C-glycoside xanthones and 12 known
xanthones from the plant Swertia punicea.123 The ve new
xanthones were identied using extensive HRESIMS and NMR
spectroscopic experiments and were named puniceasides A–E
(69a, 70a, 72a, 75a, 76a). For puniceaside B the cis congura-
tion between H-5 and H-8 was conrmed using NOESY exper-
iments. Also, it was found that the H-60 resonance pattern
indicated that two different rotameric forms of puniceaside B
exist. By heating to 120 C in a 1HNMR experiment, the two
singlets of H-60 merged into one singlet. Puniceaside C was
conrmed to be a trimeric xanthone glycoside by close exami-
nation of the results from mass spectrometric methods and
HMBC NMR experiments. As far as is known, this was the rst
trimeric xanthone reported in the literature. By subjecting the
compound to acid hydrolysis, the glycosidic moiety was found
to be D-glucose. Two more trimeric xanthones were identied
as puniceasides D and E. HMBC correlations showed the
presence of the OMe group in puniceaside E. The absolute
congurations of 75a and 76a could not be determined due to
insufficient quantities of compounds. The presence of different
rotameric congurations is likely, since heating the 1H NMR
samples to 120 C resulted in the merging of the two singlets of
H-60 into one singlet, similar to observations for puniceaside B.
Puniceasides A–E, swertiabisxanthone I 80-O-b-D-glucopyrano-
side, 3-O-demethylswertipunicoside and swertipunicoside were
tested for their neuroprotective activity against hydrogen
peroxide-induced PC12 cell damage. In particular puniceaside
B was found to be very potent with a cell viability of 98.1 6.8%
at a concentration of 25 mg mL1 compared to hydrogen
peroxide treated cells. Interestingly, swertiabisxanthone I 80-O-
b-D-glucopyranoside and 3-O-demethylswertipunicoside were
found to potently stimulate the damaged PC12 cells to grow,
resulting in cell viability scores of 123% and 158%. In 2012,
Guo et al. reported the characterisation of 16 new xanthone
compounds from extracts of Swertia punicea. Aer studying the
ESI-MS fragmentation behaviours of 17 known xanthones very
closely, they could apply this knowledge to high-performance
liquid chromatography diode-array detection/tandem mass
spectrometric results and thus identify 11 new dimeric and 4
new trimeric xanthones (69b–d, 70b and c, 71a and b, 72b, 75b,
76b, 74, 73c–e, 77c).124
4 Xanthone dimers from fungi
Fungi have yielded some beautiful xanthone dimers, the
majority of which possess a common biaryl bond as the
method of their linkage. The biaryl bond is most oen
arranged in a 2,20-manner with respect the common
xanthone hydroxyl moiety; in a couple of cases, natural
products with 2,40-biaryl bonds have been described, as has
the somewhat rarer 4,40-biaryl linkage. Additionally, the
position of methylation of the xanthone core is found at the
C3, C6 or sometimes C10a positions, which can provide
insight to the biosynthetic origin of the compounds (see
Table S-1† for structural details).This journal is © The Royal Society of Chemistry 2015

























































































View Article Online4.1 Ascherxanthones
Ascherxanthone A (78) was isolated from the methanol extract
of the mycelia of Aschersonia sp. BCC 8401, aer signicant
antimalarial activity in Aschersonia cultures was observed.125
Evidence for the symmetric homodimeric structure of ascher-
xanthone A was provided by mass spectrometry and the pres-
ence of only 16 carbon signals in the 13C NMR spectrum. The
tetrahydroxanthone structure was established on the basis of
the HMBC correlations, and using COSY and HMQC NMR
spectroscopic methods the entire structure was elucidated.
Intense correlation from the phenolic proton to the quaternary
carbon placed this carbon at C2, conrming a 2,20-biaryl-linked
dimer. Interestingly, the structure of ascherxanthone A is very
close to TMC 315A1, TMC 315A2, TMC 315B1 and TMC 315B2
(80–83); four dimeric xanthones that were isolated from Ceu-
thospora sp. TMC1678 and reported in a Japanese patent to be
RANKL (receptor activator of NF-kB ligand) antagonists that can
prevent or control osteoporosis.126 It should be noted the Japa-
nese patent does not provide any stereochemical information
for TMC 315A2 (81), which may therefore be in fact identical to
ascherxanthone B (79). Note that ascherxanthone A bears one
less hydroxyl than the other compounds in this family, and oneThis journal is © The Royal Society of Chemistry 2015component of each TMC 315B1 and B2 has been reduced to the

























































































View Article OnlineIn a search for new agents against the rice blast fungus
Magnaporthe grisea that has developed a fungicide resistance,
culture broth extracts from approximately 800 fungal strains
were investigated in an in vitro screening assay. A culture of
Aschersonia luteola BCC 8774 was found to produce ascherxan-
thone B, a compound active againstM. grisea with an IC90 value
of 0.58 mg mL1 The structure of ascherxanthone B (79) was
elucidated using COSY, HMBC and HMQC NMR experiments
and found to be almost identical to ascherxanthone A, with the
only difference being the replacement of the olenic proton at
dH 6.87 (H-8) in ascherxanthone A with a chelated hydroxy
resonating at dH 13.43 (C-8 hydroxyl, broad singlet). Interest-
ingly, it was found that ascherxanthone A was nearly inactive in
the same biological assay againstM. grisea with an IC90 value of
over 50 mg mL1.127 However, ascherxanthone A did show
signicant activity against Plasmodium falciparum K1 (IC50 ¼
0.20 mg mL1). Furthermore, it also showed cytotoxicity to Vero
cells (IC50 0.80 mg mL
1) and three cancer cell lines (IC50 values
between 1.7 and 0.16 mg mL1).1254.2 Chrysoxanthone
Chrysoxanthone, although not a xanthone dimer, is included
here as an unusual example of the mixed-biological derivative
‘xanthraquinones’, which also include the beticolins128–131 and
the xanthoquinodins.132–135 Chrysoxanthone, as reported by
Anke and co-workers,56 features a form in which 2-hydroxy-
chrysophanol is coupled to blennolide A (hemisecalonic acid B)
through a biaryl ether linkage. The authors determined the
novel structure with 2D NMR andmass spectral techniques, and
it was found to possess antimicrobial and antifungal properties.
These most likely result directly from the discrete bioactivities
of each the xanthone and anthraquinone components. This
compound, alongside the xanthoquinodins and beticolins,
represents a biosynthetic junction of a xanthone and one of its
likely biosynthetic precursors (anthraquinone). The synthesis of
an ether linkage between two xanthenes has been recently
reported by Sahin, Nieger and Bräse.136
4.3 Dicerandrols A–C
Dicerandrols A–C (84–86) were isolated from the culture broth
of the Phomopsis longicolla, an endogenous fungi from the mint
species Dicerandra frutescens. Extensive NMR experiments were
complemented by a positive FeCl3 experiment, indicating the
2,20-linkage mode of the dimer (the test is positive for a para-
unsubstituted phenol). The 1H NMR spectrum of dicerandrol C18 | Nat. Prod. Rep., 2015, 32, 6–28was found to be simple, suggesting a plane of symmetry. 2D
NMR experiments were used to determine the relative stereo-
chemistry for this compound, and by inference, those of
dicerandrol B and C.137 In 2013 the absolute congurations of
dicerandrols B and C were determined by TDDFT electronic
circular dichroism (ECD) calculations.138 It is likely that dicer-
androl A has the same absolute stereochemical conguration,
but to date only the relative conguration has been reported.
The dicerandrols have antimicrobial activities (Bacillus
subtilis and Staphylococcus aureus) with increased activities
related to the decreased degree of acetylation of the molecules
(i.e., A > B > C). The dicerandrols were also active against two
cancer cell lines, HCT-116 and A549 (colon and lung tumour,
respectively).137 In 2008, dicerandrol A was also isolated from
Phomopsis sp. PSU-D15 and used in comparison studies to
help identify a new member of the phomoxanthones (deace-
tylphomoxanthone B 101).90 Dicerandrol C was isolated from
a P. longicolla obtained from red seaweed Bostrychia radicans
and identied with the use of 1D and 2D NMR spectroscopic
methods as well as by mass spectrometry.89 Another study
performed several biological tests on dicerandrols A, B, and C
that were also isolated from P. longicolla. Using disk diffusion
assays they found that dicerandrols A and B possess anti-
bacterial activity against Xanthomonas oryzae KACC 10331, a
cause for bacterial blight in rice. Subsequently, dicerandrol A
was also tested for antimicrobial activity against seven other
X. oryzae strains, several Gram-positive and Gram-negative
bacteria, a fungus and a yeast. It was found that dicerandrol A
showed a relatively high activity in this broad spectrum of
species, although it was oen bested by commercial antibi-
otics. By performing growth and time-dependent production
of secondary metabolites studies, it was found that the
dicerandrols were produced mainly aer 4 days of fermenta-
tion and that the maximal production was at day 10. This led
to a maximal antibacterial activity aer day 14.139 These
results are useful in the production of a natural preventive
medicine against bacterial blight of rice, which is very rele-
vant since it was found that X. oryzae has developed a resis-
tance to the available antibiotics. A more detailed
continuation study on the time-dependent production of
dicerandrols and other antibacterial compounds in
P. longicolla conrmed that the optimum fermentation time
for maximal antibacterial activity of the fungus is indeed 14
days.140 Dicerandrols A–C were also isolated in 2013 from the
mycelium of a culture broth of Phomopsis longicolla S1B4 and

























































































View Article Onlineactivity test the dicerandrols A–C showed a MIC of 8, 16 and
16 mg mL1, respectively.140
The dicerandrols and the structurally similar penexanthone
A were submitted to several biological activity tests versus a
broad range of tumour cell lines.141 The majority of the in vitro
screening tests were performed in the presence of non-malig-
nant accessory cells, such as bone marrow stromal cells, since it
was found that the activities of potential drugs can be affected
by microenvironment-dependent drug resistance or sensitisa-
tion of the tumour cells.142 Among the tested compounds,
dicerandrol B was found to be the most promising candidate for
further investigations. It showed moderate activity against
Dox40, Farage, H929, HT, OPM2 and RPMI8226 cell lines in the
presence of stromal cells with IC50 values of 2.3, 1.3, 3.4, 1.3, 1.5,
and 1.2 mM, respectively. More importantly, it was found that
dicerandrol B showed a relatively low toxicity against human
immortalised non-malignant cells, such as HS-5 bone marrow
stromal cells, HOBIT osteoblast-like cells, THLE-3 hepatocytes,
and SVGp12 astrocytes, compared to the values found for cancer
cell lines RPMI8226 and H929. This relative selectivity is cause
for further investigations into the biological activity of this
compound.141 Dicerandrols A–C were also isolated from Pho-
mopsis sp. HNY29-2B and tested for their cytotoxicity against
human breast cancer, colon cancer, lung cancer, liver cancer
and breast epithelial cell lines. Dicerandrol A showed a broad
anti-tumour activity, but was also cytotoxic to the breast
epithelial cells. Dicerandrol B and penexanthone A (101)
showed also some cytotoxicity to the cancer cells, but were
found to be more selective and less strongly damage the breast
epithelial cells. In this assay dicerandrol C was found to be not
very cytotoxic, suggesting that the free hydroxy groups are
important as a key pharmacophore.143 In a study that mainly
focusses on the biological activity of phomoxanthone A (106),
dicerandrols B and C are also investigated. It was found that the
dicerandrols were both cytotoxic to murine lymphoma cancer
cell lines (IC50 values of 10 and 1.1 mM, respectively) and that
dicerandrol C is slightly pro-apoptotic.1384.4 Ergochromes
Ergochrome dimers comprise a colourful group of xanthones
rst reported by Kra in 1906 as a single compound of the
formula C14H14O6 aer separation from Claviceps purpurea.144
The contamination of rye with ergochrome-containing C. pur-
purea led to epidemics known as ergotism or ‘St. Anthony's Fire’
in middle-ages Europe. The mixture of toxins produced by this
fungus was responsible for the toxicity and debilitating effects
on the affected population. The ergochrome dimers (21, 23, 87
to 99, Fig. 3) include the wide-spread secalonic acids, ergo-
chrysins, ergoavins and chrysergonic acid, many of which
possess a huge variety of potent bioactivities. The ergochrome
dimers are composed of several monomeric units (hemi-
secalonic acids A–F, aka ‘blennolides’),47 which are arranged in
a variety of dimers and heterodimers. In all known secalonic
acids, the methyl and methoxycarbonyl substituents are found
to be trans-congured. Whilst secalonic acids are ester homo-
dimers, other heterodimer ergochromes are known. ForThis journal is © The Royal Society of Chemistry 2015example, ergochrysins are lactone/ester heterodimers, ergo-
avin is a homodimer,145 whilst ergoxanthin has undergone
structural rearrangement to form a pendant butyrolactone ring
on one half of the molecule.146
Due to the early time at which they were rst studied,
modern spectral methods were not applicable to facilitate the
structural elucidation of the ergochromes, and early structural
assignations on these compounds were frequently revised in
later years. For example, the initial misidentication of ergo-
chrysin and ergoavin as secalonic acids was later revised by
Bergmann in 1932 as dimers with the formula C28H28O12.147 A
number of papers followed in the 1950s to 70s, over which time
more secalonic acids were isolated and identied. One major
point of contention in the early days of exploration of this
compound class was as to whether the natural products were
2,20-, 4,40- or even 2,40-linked.148,149 The biaryl linkage was nally
denitively assigned as 2,20-linked when Mayo and Aberhart
reported on the isolation, in crystalline form, of six compounds
from a Portuguese ergot drug in 1965.150 In contrast to earlier
reports,151 these authors showed that ergochrome dimers
ubiquitously gave positive results in the Gibbs test, indicating
the presence of an unsubstituted aryl methine in a position
para- to the phenolic moiety, and thus a 2,20-linkage.
A comprehensive analysis of the ergochrome constituents of
C. purpurea by Franck and co-workers led to the reporting of a
total of ten component compounds, including a new homo-
dimer named ergochrome DD (94, Fig. 3), as well as the
remaining six heterodimers possible with a combination of one
subunit of each of those four species A, B, C and D. The majority
of which they identied as the ergochromes are diastereomeric
at positions 6,60, 5,50, 10 and 100. The authors also identied the
absolute stereochemistry at these centres.152
Büchi and co-workers reported novel secalonic acid F (88,
ergochrome BE) and secalonic acid D (91, ergochrome EE) in
1977, following isolation from the fungus Aspergillus aculea-
tus.153 The following year, then-novel secalonic acid G (90) was
isolated alongside secalonic acids A and E from Pyrenochaeta
terrestris and the structure elucidated by CD and NMR
spectroscopy.23
Secalonic acid D (SAD) is a major environmental toxin, being
isolated from Penicillium oxalicum, a major microbial contam-
inant of freshly-harvested corn (in one study present on 44% of
pre-harvest corn crops).154 Teratogenic effects were observed in
the development of rats that were exposed to SAD injected
during fetal development. SAD was lethal to mice when injected
intraperitoneally in the 25–50 mg kg1 range.155 The teratogenic
and toxic nature of these compounds is alarming in light of
their propensity to contaminate foodstuffs.156 The rate of birth-
defects and teratogenicity-initiated spontaneous abortions in
humans is also alarmingly frequent.
Despite the widespread occurrence of the ergochromes,
none had been synthesised until the end of 2013, and neither
had any other xanthone dimers or trimers. In early 2014,
Porco and co-workers at long last described the synthesis of
secalonic acids A and D, utilising a Cu(I) catalysed di-
destannylative coupling.157,158 This reaction represents a
signicant breakthrough for the study of the xanthoneNat. Prod. Rep., 2015, 32, 6–28 | 19

























































































View Article Onlinedimers,62 and may open up the eld to the synthesis of
interesting analogues for medicinal chemistry studies.
Recent advances in Ullmann coupling may make the strategy
of Whalley and co-workers towards ergoavin a more feasible
route to the natural products than was originally the case in
1971.159 Bräse and co-workers have described a novel one-pot
methodology for the synthesis of symmetrical biaryls160 as a
part of their ongoing investigations in the synthesis of the
secalonic acids. Sahin, Nieger and Bräse have also published
on the oxidative coupling of various hexahydroxanthenols.
The application of an iron complex as an oxidant converted 2-
hydroxy substituted xanthenes to the 3,30-bis-coupled bix-
anthenes.136 It appears that these two papers represent, until
the end of 2013, the only successful chemistry published on
the topic of xanthone or xanthene biaryl-coupling.20 | Nat. Prod. Rep., 2015, 32, 6–284.5 Neosartorin
Neosartorin (100) was isolated in 1998 from the cultured
mycelium of the soil mould Neosartorya scheri. A combina-
tion of 2D NMR experiments determined that neosartorin
was an isomer of eumitrin A1. However, close examination of
the long range coupling constants of nuclei around the two
arene units revealed a 2,40-biaryl linkage instead of the 4,2-
linkage found in eumitrin A1.161 A closer investigation of the
low-intensity long-range NOEs by a 1D double-pulsed eld
gradient spin-echo NOESY NMR experiment resulted in
conrmation of the relative conguration of the two
xanthone subunits. The absolute stereochemistry of neo-
sartorin was axially P and found to be
(aR,5S,10R,50S,60S,100R), this was determined on the basis of
its electronic circular dichroism (ECD) spectra in conjunc-
tion162 with TDDFT-ECD calculations. They found that the

























































































View Article Onlinethe two subunits was stabilised by long-range nonbonding
interactions between the substituents of different xanthone
units.163
A taxonomical study of Aspergillus species conducted in 2005
reports the production of neosartorin in the new species A.
lentulus, A. fumigatiaffinis and A. novofumigatus, but not in A.
fumigatus. The presence of neosartorin was based on evaluation
of UV spectral evidence. Based on these ndings and other
similarities the authors conclude that the taxa of Neosartorya
scheri and the Aspergillus species are chemically related.164
Neosartorin was found to show a strong activity against Gram-
positive bacteria such as Staphylococcus aureus (MIC: 8 mg mL1)
and Bacillus subtilis (MIC: 4 mg mL1), while it did not affect the
tested Gram-negative bacteria. In cytotoxicity tests against
several cancer cell lines it scored very badly, showing almost no
notable cytotoxicity.1624.6 Penexanthone A
Recently, Clardy et al.141 isolated dicerandrols A–C and a novel
dimeric xanthone named penexanthone A (101) fromCR1642D, a
Penicillium sp. obtained from the Costa Rican rainforest. The
structure, including relative conguration, of penexanthone A
was elucidated using mainly 2D NMR techniques (HSQC, HMBC,
NOESY and ROESY) and molecular modelling with Chem3D
Ultra (9.0). The two monomers were found to be connected
through a 2,40-linkage. The dicerandrols were identied by
comparison of several physical and spectroscopic data sets (UV,
IR, 1H NMR, [a]D and MS) with the literature values. The authors
note that the structure of penexanthone A was already reported in
a Korean patent, although the 1H NMR spectra was unclean,
suggesting an impure sample.165 Penexanthone A is identical to
monodeacetylated phomoxanthone B (vide infra). Penexanthone
A was submitted to several biological activity tests versus a broadThis journal is © The Royal Society of Chemistry 2015range of tumour cell lines, however the observed IC50 values
indicate that penexanthone A is only weakly active in the pres-
ence of stromal cells.141 Penexanthone A was also isolated from
Phomopsis sp. HNY29-2B and tested for its cytotoxicity against
human breast cancer, colon cancer, lung cancer, liver cancer and
breast epithelial cell lines. The dimeric xanthone showed rela-
tively high cytotoxicity to the cancer cells and a reduced cyto-
toxicity towards the immortalised breast epithelial cells, which is
a very useful feature when developing new anti-cancer drugs.1434.7 Penicillixanthone
The 2,40-biaryl-linked dimer penicillixanthone was reported
around ten years ago88,166 by Chinese groups, who described the
absolute stereochemistry. This compound has been re-isolated
in 2013.167
4.8 Phomalevones
In 2011, phomalevones A–C (103–105) were isolated from a
Hawaiian isolate of Phoma sp. (MYC-1734 ¼ NRRL 39060; Cucur-
bitariaceae). The structures of phomalevones A–Cwere determined
by detailed analysis of NMR and MS data.168 The absolute cong-
uration of the sp3 stereogenic centres of phomalevone A were
revealed by analysis of NMR spectra of Mosher type derivatives.
Phomalevone A was found to resemble ascherxanthone B.
The 13C NMR spectrum of phomalevone B showed only 15
carbon signals, thus indicating a symmetrical, homodimeric
structure. Via HR-ESI-MS data it was determined that phoma-
levone B is an isomer of phomalevone A. However, the NMR
spectra showed a signicant downeld shi of the only carbonyl
signal relative to its location in the spectrum of phomalevone A
and the presence of two sp2 carbon signals instead of sp3 signals
as in the spectrum of phomalevone A. By comparing the NMR
spectroscopic data with that of acremonidin D,169 a symmetrical
dimer with two benzophenone monomer units connected via a
methylene linkage, a structural assignment could be made.168
The occurrence of phomalevone A together with the benzo-
phenone analogue, phomalevone B, is consistent with several
reports that hydroxylated benzophenones are very likely to be
key intermediates in xanthone biosynthesis.25,170,171 HMBC
spectra of phomalevone C revealed its heterodimeric nature,
with one subunit the same as the monomer unit in phomale-
vone A, while the other has one secondary alcohol group oxi-
dised to a carbonyl group. Phomalevones A–C showed
antibacterial activity in agar disk diffusion assays at 100 mg per
disk against Bacillus subtilis and Staphylococcus aureus. Addi-

























































































View Article Onlinealbicans and Escherichia coli and phomalevone C showed activity
against Fusarium verticillioides and Aspergillus avus (IC50 value




The antimalarial activity of methanolic extracts of mycelia of the
endophytic fungus Phomopsis sp. BCC 1323 led to researchers
isolating and identifying phomoxanthones A and B (106, 109).
The relative stereochemistry could be determined by synthe-
sising a deacetyl derivative of phomoxanthone A and comparing
the change in coupling signals. Phomoxanthone A and B were
the rst reported examples of naturally occurring xanthone
dimers with 4,40 or 2,40 linkages.172 In 2008, the deacetyl deriv-
ative of phomoxanthone B (110) was isolated from the same
fungus species by Kirtikara et al.90 Phomolactonexanthone A
and B are both derived either from coupling of a lactone-
analogue of a xanthone (as the blennolides)47 and a xanthone
itself, or from further derivatisation from a dimeric xanthone.
Biological tests with deacetylphomoxanthone B showed a
higher antibacterial effect against the pathogen Xanthomonas
oryzae KACC 10331, a cause for bacterial blight in rice, than a
positive control with 2,4-diacetyphloroglucinol.139 Deacetyl-
phomoxanthone B and C (108) and phomolactonexanthone A
and B (111, 112), that were isolated from Phomopsis sp. HNY29-
2B, were tested for their cytotoxicity against a series of human
cancer lines and it was found that while deacetylphomox-
anthone B has a reasonable cytotoxicity against all tested cancer
cell lines, deactylphomoxanthone C and the phomolactonex-
anthones were virtually inactive against all cell lines.143 Pho-
moxanthone A and B showed antimalarial (Plasmodium
falciparum K1, multi drug resistant strain, IC50 of 0.11 and 0.33
mg mL1, compared to IC50 of 0.16 and 0.0011 mg mL
1 for
chloroquine diphosphate and artemisinin, respectively) and22 | Nat. Prod. Rep., 2015, 32, 6–28antitubercular activity (Mycobacterium tuberculosis, H37Ra
strain, IC50 of 0.5 and 6.25 mg mL
1, compared to IC50 of 0.05
and 2.5 mg mL1 for isoniazid and kanamycin sulfate, respec-
tively). Biological tests on cancer cell lines (KB cells, BC-1 cells
and Vero cells) showed that the natural products are cytotoxic
(IC50 mg mL
1; 0.51–1.4 for phomoxanthone A and 0.7–4.1 for
phomoxanthone B), although it was noted that standard drugs
are more potent in both the bacterial and cancer cells tests. The
deacetyl derivative was also investigated in these assays and was
found to be mostly inactive in all the tests – it is speculated that
this might be due to its lower lipophilicity.172
The absolute conguration (aS,5R,6R,10 aR,50R,60R,10a0R) of
phomoxanthone A was determined by a combination of single
crystal X-ray analysis with measured and calculated CD spectra,
in 2005.86 However, in 2013 the absolute conguration was
revised to be (aR,5S,6-S,10 aS,50S,60S,10a0S), when a team of
researchers performed a detailed X-ray analysis study and
TDDFT-ECD calculations aer they suspected that the cong-
uration might have been wrongfully assigned.138 The suspicion
arose when they isolated phomoxanthone A together with
dicerandrols B and C from Phomopsis longicolla and found that
all their stereocenters had the S absolute conguration. In this
same study they also found a new natural product from the
same endophyte, which was identied by NMR studies as
12-deactylphomoxanthone A (107).
Biological tests showed that phomoxanthone A has prom-

























































































View Article OnlineLee et al. isolated several secondary metabolites from the
mycelium of a culture broth of Phomopsis longicolla S1B4,
including dicerandrols A–C (84–86) and a compound they
named deacetylphomoxanthone B, 101 (which is in fact a mon-
odeacetylphomoxanthone and is identical to penexanthone A).
This compound exhibits a strong antimicrobial activity against
gammaproteobacteria Xanthomonas oryzae with a MIC of 32 mg
mL1, compared to dicerandrols A–C which showed 8, 16 and
16 mg mL1 respectively.140 Phomoxanthone A has also been
found to strongly inhibit the proliferation of the murine
lymphoma cell line L5178Y, as well as other cell lines, including
some cisplatin resistant cancer cell lines.138 Remarkably, the
cytotoxicity of phomoxanthone A towards the lymphoma cells
was found to be increased over 100-fold with respect to healthy
blood cells. A semisynthetic fully deacetylated phomoxanthone
A showed no activity in this assay. Proksch et al. also analysed
the apoptosis inducing potential of phomoxanthone A by ow
cytometric analyses of hypodiploid nuclei in Jurkat T cells.138
The presence of these hypodiploid nuclei is indicative of
aspartate-directed cysteine protease (caspase) induced DNA
fragmentation, which is an indicator for apoptosis. They found
that among all tested substances the 4,40-linked phomox-
anthone A and deacetylphomoxanthone A scored highest on
these tests and actively induce apoptosis. On top of that, they
also found that they activate immune effector functions in
murine immune cells, such as primary T lymphocytes, NK cells
and macrophages, as was observed by the upregulation of cell-
type specic activation markers. During a preliminary struc-
ture–activity assessment the authors conclude that the presence
of the acetyl groups and the 4,40-linked system in xanthone
dimers 106 and 107 are important to maintain the interesting
biological properties, possibly because of an underlying mech-
anism where there is a necessity to pass the cellular membrane.
The deacetylated xanthones are less lipophilic and therefore
oen score very low on biological tests.
When comparing the overall activity of the phomoxanthones
with other similar xanthones, it must indeed be noted that the
acetylated species, such as the dicerandrols and neosartorin,This journal is © The Royal Society of Chemistry 2015oen show quite interesting biological properties, whereas more
oen the non-acetylated compounds either were not tested, or
did not show promising activities. One could speculate that this
is possibly due to enhanced cell penetration, however, in the
case of the dicerandrols, the more acetylated dicerandrol C was
found to be much less cytotoxic to cancer cells than the dicer-
androls A and B that have free hydroxyl groups.4.10 Rugulotrosins
Rugulotrosins A and B (113, 114) were isolated from cultures of
Penicillium sp. derived from Australian soil samples. Rugulo-
trosin A is symmetrically 2,20-linked while rugulotrosin B is a
2,40 linked dimer. The structures of these compounds were
determined by NMR and MS techniques, and supported by
single crystal X-ray analysis of rugulotrosin A. The compounds
were of considerable activity against several microbial species
(Bacillus subtilis, Enterococcus faecalis and Bacillus cereus).1734.11 Talaroxanthone
The identity of talaroxanthone (25) was reported by Koolen and
co-workers in 2013. This compound, featuring a 4,40-linked
biaryl motif, was isolated from the culture broth of DgCr22.1b,
an endophytic Talaromyces sp. fungi isolated from the healthy
tissue of the medicinal plant Duguetia stelechantha in the
Amazonian rainforest. The yellow powder that was subse-
quently isolated by chromatographic techniques was deter-
mined to be the structure shown by HRMS and several 2D NMR
techniques. Whether the medicinal qualities of the plant
material are due to the presence of this fungal-derived
compound is as yet unclear.574.12 Xanthonol
The unsymmetrical 2,20-biaryl-linked dimeric xanthone, xan-
thonol (115), was isolated from the fermentation broth of a non-
sporulating fungi found in the leaf litter of the plant Manikara
bidentata. Xanthonol bears the methyl-substituents in the aryl
positions, rather than the 6,60-methylation of the ergochromes
etc. Also interesting is the benzoylated alcohol at the C50 posi-
tion. Xanthonol is an anthelmintic, as revealed by tests upon
the larvae of Lucilia sericata, Aedes aegypti, and Haemonchus
contortus.174Nat. Prod. Rep., 2015, 32, 6–28 | 23

























































































View Article Online5 Xanthone dimers from lichens
5.1 Eumitrins
In 1967 Asahina rst reported the occurrence of yellow
pigments named eumitrins A1, A2, B and T (116–119) isolated
from the lichen Usnea baileyi.175 Eumitrins A and B were later
isolated from benzene extracts of the dried lichen thalli.176
Shibata et al. found that the fraction of eumitrin A could be
separated into A1 and A2 by recrystallisation and elucidated the
chemical structures of eumitrins A1, A2 and B by spectroscopic
methods.177 By measuring differences in chemical shis in
NMR experiments aer acetylation of the compounds, they were
able to assign the biphenyl junction in these dimers as a 4,20-
linkage. Using single-crystal X-ray analysis of a tribromo deriv-
ative of eumitrin B they conrmed the structures of eumitrins
A1, A2 and B. Interestingly, these xanthones have been reduced
down from their normal oxidation states to bear a non-
oxygenated/non-aromatic cyclohexenyl C-ring.
In 2002 a Japanese patent was led, claiming that eumitrins
A1 and A2 could be used as inhibitors for nitric oxide formation by
macrophages and thus be useful for a wide range of illnesses.178
Elix et al. report the extraction of secalonic acid A and eumitrin T24 | Nat. Prod. Rep., 2015, 32, 6–28from the lichen-forming fungus Physconia distort. Interestingly,
they found that these dimeric xanthones were only found when
intact lichen thalli were investigated and not in axenic cultures of
the fungus, indicating a clear difference in metabolic pathways
between the lichen and the axenic fungus.92 Recently, the same
group investigated the contents of 18 lichen obtained from the
mountainous areas of Malaysia using TLC and HPLC analyses.
Amongst the secondary metabolites found in the lichen Usnea
baileyi they found eumitrins A1, A3, B1 and B2. However, the
structures of eumitrins A3 and B2 are not yet elucidated.179
5.2 Hirtusneanoside
Hirtusneanoside A (120) was rst isolated from the lichen Usnea
hirta in 2007 by Řezanaka and Sigler, and found to be a
L-rhamnose-O-deoxyglycoside of an unsymmetrical dimeric tet-
rahydroxanthone.180 Fascinatingly, hirtusneanoside features an
additional methyl in relation to the secalonic acids; the
biosynthetic origin of this methyl group is as yet unknown.
Hirtusneanoside A is effective against Staphylococcus aureus and
Bacillus subtilis.
5.3 Unnamed dimeric xanthones
A number of unnamed xanthones have been reported, some due

























































































View Article Onlinepatent applications (Fig. 4). In compound 125, the lactone
bridge appears to have been reductively transformed to a furan.
6 Conclusions
Dimeric xanthones are a structurally highly diverse group of
compounds from various kingdoms of organisms, including
plants, fungi and lichens. We have reviewed their origins,
structural features, and, where applicable, bioactivities. Within
the last ve years, a number of monomeric xanthones have been
prepared16 and the rst synthesis of ergochromes has been
achieved. We assume that in the next decade or so – with the
further advent of arylation methods suitable for the unique
requirements of these species – the synthesis of dimeric
xanthones will be tackled with success.
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